Abstract
We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response. Results: mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44% showed DST nonsuppression (41% maprotiline, 45% trazodone).Seventy-six per cent of the patients responded to treatment (76% for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86% maprotiline, 88% trazodone) and 68% of the suppressors responded (70% maprotiline, 67% trazodone). Of the eight treatment non-responders six showed DST suppression. The implications of these findings are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 313-317 |
| Number of pages | 5 |
| Journal | Journal of Psychiatric Research |
| Volume | 21 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 1 1987 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry
- Psychology(all)
Cite this
The dexamethasone suppression test and antidepressant response in major depression. / Simon, Jeffrey S.; Evans, Dwight Landis; Nemeroff, Charles.
In: Journal of Psychiatric Research, Vol. 21, No. 3, 01.01.1987, p. 313-317.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The dexamethasone suppression test and antidepressant response in major depression
AU - Simon, Jeffrey S.
AU - Evans, Dwight Landis
AU - Nemeroff, Charles
PY - 1987/1/1
Y1 - 1987/1/1
N2 - We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response. Results: mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44% showed DST nonsuppression (41% maprotiline, 45% trazodone).Seventy-six per cent of the patients responded to treatment (76% for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86% maprotiline, 88% trazodone) and 68% of the suppressors responded (70% maprotiline, 67% trazodone). Of the eight treatment non-responders six showed DST suppression. The implications of these findings are discussed.
AB - We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response. Results: mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44% showed DST nonsuppression (41% maprotiline, 45% trazodone).Seventy-six per cent of the patients responded to treatment (76% for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86% maprotiline, 88% trazodone) and 68% of the suppressors responded (70% maprotiline, 67% trazodone). Of the eight treatment non-responders six showed DST suppression. The implications of these findings are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0023549414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023549414&partnerID=8YFLogxK
U2 - 10.1016/0022-3956(87)90033-1
DO - 10.1016/0022-3956(87)90033-1
M3 - Article
C2 - 3681765
AN - SCOPUS:0023549414
VL - 21
SP - 313
EP - 317
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
SN - 0022-3956
IS - 3
ER -